Should Regulators Rely More on AI to Accelerate Drug Approvals?

AI is increasingly being used across the drug development lifecycle, from discovery and clinical trials to regulatory review. As data volumes grow and timelines remain a critical concern, regulators are beginning to assess how AI tools could support faster, more efficient evaluation of new therapies.

Recent developments highlight this shift, as the FDA is deploying AI tools to support regulatory workflows and piloting real-time clinical trial monitoring to help accelerate drug approvals, with human oversight built into the process.

Proponents suggest that AI could enhance data analysis, identify patterns more quickly and streamline regulatory workflows, potentially accelerating access to new treatments. At the same time, questions remain around transparency, validation, bias and the need for human oversight in high-stakes decision-making. As regulatory agencies consider how to integrate these technologies, the balance between speed, safety and trust remains central.

Should regulators rely more on AI to accelerate drug approvals? Cast your vote below and join the conversation.

Got a poll idea you’d like us to feature? Share it with us!